| |
All (31,475)
|
AMC (20,138)
|
AMX (11,337)
|
p-value
|
|---|
|
Age, median* (IQR)
|
69 (62–76)
|
69 (62–77)
|
69 (61–76)
|
< 0.0001
|
|
Age*
| | | |
0.0008
|
|
≤ 62
|
7737
|
4823 (24%)
|
2914 (26%)
|
|
63–69
|
7231
|
4594 (23%)
|
2637 (23%)
|
|
70–77
|
8713
|
5644 (28%)
|
3069 (27%)
|
|
≥ 78
|
7794
|
5077 (25%)
|
2717 (24%)
|
|
Gender female*
|
16,431
|
10,471 (52%)
|
5960 (53%)
|
0.33
|
|
FEV1*
| | | |
< 0.0001
|
|
FEV1 ≥ 80%
|
1942
|
1121 (6%)
|
821 (7%)
|
|
50% ≤ FEV1 ≤ 80%
|
12,774
|
7934 (39%)
|
4840 (43%)
|
|
30% ≤ FEV1 ≤ 50%
|
11,661
|
7671 (38%)
|
3990 (35%)
|
|
FEV1 ≤ 30%
|
5098
|
3412 (17%)
|
1686 (15%)
|
|
Exacerbations within the past year*
|
0
|
17,791 (88%)
|
10,143 (89%)
|
0.0028
|
|
1
|
1601 (8%)
|
782 (7%)
|
|
≥ 2
|
746 (4%)
|
412 (4%)
|
|
BMI, median* (IQR)
|
25.0 (21.5–29.0)
|
25.0 (21.0–29.0)
|
25.0 (22.0–29.0)
|
< 0.0001
|
|
BMI* (kg/m2)
| | | |
0.0011
|
|
10.0–18.4
|
2810
|
1853 (9%)
|
957 (8%)
|
|
18.5–24.9
|
12,308
|
7964 (40%)
|
4344 (38%)
|
|
25.0–29.9
|
9497
|
6045 (30%)
|
3452 (30%)
|
|
≥ 30
|
6860
|
4276 (21%)
|
2584 (23%)
|
|
Smoking*
|
0.0022
|
|
Current smokers
|
10,802
|
6787 (34%)
|
4015 (35%)
|
|
Ex-/Non-smokers
|
20,673
|
13,351 (66%)
|
7322 (65%)
|
|
Prednisolone treatment for exacerbation*
|
No prednisolone
|
17,769 (88%)
|
10,189 (90%)
|
< 0.0001
|
|
Short course treatment
|
1899 (9%)
|
918 (8%)
|
|
Long course treatment
|
470 (2%)
|
230 (2%)
|
|
Comorbidities
|
|
Cardiovascular disease
|
10,838
|
6860 (34%)
|
3978 (35%)
|
0.07
|
|
Diabetes mellitus*
|
1893
|
1165 (6%)
|
728 (6%)
|
0.0231
|
|
Renal failure
|
682
|
416 (2%)
|
266 (2%)
|
0.11
|
|
Depression
|
453
|
278 (1%)
|
175 (2%)
|
0.26
|
- * Significant difference found between the two groups (p < 0.05)
